Thiazolidinediones plus metformin association on body weight in patients with type 2 diabetes

被引:21
作者
Derosa, G. [1 ]
Maffioli, P. [1 ]
机构
[1] Univ Pavia, Dept Internal Med & Therapeut, Fdn IRCCS Policlin S Matteo, I-27100 Pavia, Italy
关键词
Pioglitazone; Rosiglitazone; Metformin; Type; 2; diabetes; Body weight; DOSE COMBINATION THERAPY; ORAL GLUCOSE-TOLERANCE; INSULIN-RESISTANCE; DOUBLE-BLIND; GLYCEMIC CONTROL; CARDIOVASCULAR RISK; METABOLIC SYNDROME; DRUG-THERAPY; PPAR-GAMMA; ADD-ON;
D O I
10.1016/j.diabres.2010.08.001
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
There are different studies about the efficacy and safety and tolerability of thiazolidinediones added to metformin. The reported improved glycemic control with thiazolidinediones use seems to be associated with an increase in weight with an estimated 2-3 kg weight gain suggesting that maybe thiazolidinediones are not safe for the clinical use. Other authors reported that thiazolidinediones give an improvement in the glycemic without giving weight gain. With our review, we want to evaluate the effects of thiazolidinediones plus metformin combination in diabetic patients on the body weight. From the data emerged from our review we can conclude that even if a small increase in mean body weight was observed in patients treated with thiazolidinediones plus metformin therapy, the weight gain was less than previously reported and it was also considerably less than what might have been expected given the large improvements in glycemic control. For these reasons we can safely say that thiazolidinediones in combination with metformin are effective and well tolerated in patients with type 2 diabetes. (C) 2010 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码:265 / 270
页数:6
相关论文
共 48 条
[1]   Treating insulin resistance in type 2 diabetes with metformin and thiazolidinediones [J].
Bailey, CJ .
DIABETES OBESITY & METABOLISM, 2005, 7 (06) :675-691
[2]   Avandamet: combined metformin-rosiglitazone treatment for insulin resistance in type 2 diabetes [J].
Bailey, CJ ;
Day, C .
INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2004, 58 (09) :867-876
[3]   Rosiglitazone/metformin fixed-dose combination compared with uptitrated metformin alone in type 2 diabetes mellitus: A 24-week, multicenter, randomized, double-blind, parallel-group study [J].
Bailey, CJ ;
Bagdonas, A ;
Rubes, J ;
McMorn, SO ;
Donaldson, J ;
Biswas, N ;
Stewart, MW .
CLINICAL THERAPEUTICS, 2005, 27 (10) :1548-1561
[4]   Drug therapy - Metformin [J].
Bailey, CJ ;
Turner, RC .
NEW ENGLAND JOURNAL OF MEDICINE, 1996, 334 (09) :574-579
[5]   Efficacy and tolerability of vildagliptin vs. pioglitazone when added to metformin: a 24-week, randomized, double-blind study [J].
Bolli, G. ;
Dotta, F. ;
Rochotte, E. ;
Cohen, S. E. .
DIABETES OBESITY & METABOLISM, 2008, 10 (01) :82-90
[6]   Sensitivity effect of rosiglitazone on insulin and body composition in type 2 diabetic patients [J].
Carey, DG ;
Cowin, GJ ;
Galloway, GJ ;
Jones, NP ;
Richards, JC ;
Bisivas, N ;
Doddrell, DM .
OBESITY RESEARCH, 2002, 10 (10) :1008-1015
[7]   Comparison of effect of pioglitazone with metformin or sulfonylurea (monotherapy and combination therapy) on postload glycemia and composite insulin sensitivity index during an oral glucose tolerance test in patients with type 2 diabetes [J].
Ceriello, A ;
Eckland, DJ ;
Johns, D ;
Gilmore, KJ ;
Widel, M ;
Tan, MH .
DIABETES CARE, 2005, 28 (02) :266-272
[8]   Long-term efficacy and tolerability of add-on pioglitazone therapy to failing monotherapy compared with addition of gliclazide or metformin in patients with type 2 diabetes [J].
Charbonnel, B ;
Schernthaner, G ;
Brunetti, P ;
Matthews, DR ;
Urquhart, R ;
Tan, MH ;
Hanefeld, M .
DIABETOLOGIA, 2005, 48 (06) :1093-1104
[9]  
Cheng-Lai A, 2000, Heart Dis, V2, P326
[10]   PREDOMINANT ROLE OF GLUCONEOGENESIS IN INCREASED HEPATIC GLUCOSE-PRODUCTION IN NIDDM [J].
CONSOLI, A ;
NURJHAN, N ;
CAPANI, F ;
GERICH, J .
DIABETES, 1989, 38 (05) :550-557